From a medical point of view, the infant's body should be considered as a being that adapts quickly, but is also susceptible to negative aspects of the process, leading to irreversible changes that do not have time to fully manifest themselves ... Since all anatomical, physiological, biochemical and histological formations of the body from birth to 1 year are not yet fully completed, and even some organ systems They have not fully formed their functions, and external influences can harm the body's resistance. It is the complexity of the kidney structure among the organs, their incomplete formation and the absence of some cells in their histological structure that create the conditions for the development of irreversible changes.…

kidney tissue, inclusions, newborns. glomeruli, tubules, mesangial cells.

West G.D. Childhood membranoproliferative glomerulonefritis: An approach to management.// Kidney Int.-1986..-Vol. 29 № 8.-P. 1077-1093.

Schmit H., Bohle A. Tubulointerstitial alternations in type I membranoproliferative glomerulonephritis. An investigation of 259 cases.// Path. Res. Pract. 1987.-Vol.182, №1-P.6-10.

Peruzzi L., et al. Tubulointerstitial responses in the рrogression of glomerular disseases: albuminuria modulates alpha-beta 5 integrin. Kidney Int. 1996 Oct; 50(4)1310-20.

Mactier R., et al. The natural History of embranous nephropathy in the west skotland.// Quart J. Med., New Sep.-1981.-Vol.60, № 232.-P.946-956.

Honkanen E. et al. Membranous glomerulonephritis in rheumatoid arthritis not related to goldor d-penicilamine therapy: a report of four cases and review of the literature.//Clin. Nephrol. -1986.-Vol.18. № 2.-P. 87-93.

Zucchelli P., Cagnoli L., Pasquali S et al. Clinical and morphologic evolution idiopathic membranous efropathy.// Clin Nephrol.- 1986.- Vol. 25.

Beck LH, Bonegio RG, Lambeau G. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361(1):11, 2009. doi: 10.1056/NEJMoa0810457

Fervenza FC, Appel GB, BarbourSJ, et al: Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381(1):36-46, 2019. doi: 10.1056/NEJMoa1814427

Ronco P, Debiec H. Molecular pathogenesis of membranous nephropathy. Annu Rev Pathol Mech Dis. 2020. 15:287–313 2.

Alsharhan L, Beck LH. Membranous Nephropathy: Core Curriculum 2021. Am J Kidne Dis. 2020; XX(XX):1-14. doi:10.1053/j.ajkd.2020.10.009 3.

Xu Z, Chen L, Xiang H et al. Advances in Pathogenesis of Idiopathic Membranous Nephropathy. Kidney Dis. 2020 Sep 6(5): 330-345. doi: 10.1159/00050770